The US Government has notified Emergent BioSolutions of its intention to award a sole source contract for 44.75 million doses of BioThrax, the only anthrax vaccine licensed by the US Food and Drug Administration .

Emergent anticipates finalising a contract for BioThrax in the third quarter of 2011.

BioThrax is manufactured from a culture filtrate, made from a non-virulent strain of Bacillus anthracis.

To date, Emergent has delivered more than 42 million doses of BioThrax to the US Government, and more than ten million doses have been administered to military personnel.